Document is current
Any future updates will be listed below
-
Authors
Ma, Ruixue
Zhang, Qi
Liu, Yang
Li, Hujun
Chen, Huimin
Zhang, Qianqian
Qiao, Jianlin
Qi, Kunming
Shen, Guifang
Sun, Cai
Song, Xuguang
Cao, Jiang
Cheng, Hai
Zhu, Feng
Yan, Zhiling
Sang, Wei
Li, Depeng
Sun, Haiying
Zheng, Junnian
Li, Zhenyu
Xu, Kailin
Chen, Wei https://orcid.org/0000-0001-5480-6577
-
Funding
Funding for this research was provided by:
Suqian Key Laboratory of Hematology (M202111)
Natural Science Foundation of Jiangsu Province (BK20221218)
Development Fund of Affiliated Hospital of Xuzhou Medical University (XYFY2021001)
- License Information
-
More Information
Article History
Received: 7 July 2024
Accepted: 21 August 2024
First Online: 4 September 2024
Declarations
:
: The authors declare no competing interests.
: The study protocol was approved by the human studies review board at the Affiliated Hospital of Xuzhou Medical University (ClinicalTrials.gov # NCT02782351). All patients provided written informed consent before received CAR-T cell therapy. The clinical investigation was conducted according to the principles of the Declaration of Helsinki.
